What is Atb Cap Markets' Forecast for OGI FY2025 Earnings?

Key Points

• Analysts at Atb Cap Markets have lowered their FY2025 EPS estimate for Organigram Global from $0.07 to $0.05, while the current consensus estimate stands at ($0.19) per share.
• Wall Street Zen has downgraded Organigram Global’s stock from a "hold" rating to a "sell" rating.
• In its most recent quarterly earnings report, Organigram Global reported an EPS of ($0.03), missing analyst expectations and generating revenue of $50.49 million compared to estimates of $68.04 million.

Organigram Global Inc. (NASDAQ:OGI - Free Report) - Equities research analysts at Atb Cap Markets reduced their FY2025 earnings per share estimates for shares of Organigram Global in a research report issued on Wednesday, August 13th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings per share of $0.05 for the year, down from their prior estimate of $0.07. The consensus estimate for Organigram Global's current full-year earnings is ($0.19) per share. Atb Cap Markets also issued estimates for Organigram Global's FY2027 earnings at $0.04 EPS.

Organigram Global (NASDAQ:OGI - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). The firm had revenue of $50.49 million for the quarter, compared to the consensus estimate of $68.04 million. Organigram Global had a net margin of 2.86% and a negative return on equity of 8.19%.

Separately, Wall Street Zen lowered Organigram Global from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th.

Organigram Global Price Performance

Shares of OGI traded up $0.0350 during trading hours on Monday, hitting $1.5350. 515,223 shares of the company were exchanged, compared to its average volume of 727,140. The company has a market capitalization of $205.77 million, a PE ratio of 30.91 and a beta of 1.45. The firm has a fifty day simple moving average of $1.43 and a 200-day simple moving average of $1.27. Organigram Global has a one year low of $0.85 and a one year high of $2.05.

Institutional Trading of Organigram Global

Hedge funds and other institutional investors have recently modified their holdings of the business. Two Sigma Securities LLC acquired a new position in Organigram Global in the 4th quarter valued at approximately $26,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Organigram Global during the first quarter valued at $30,000. Oxford Asset Management LLP acquired a new stake in Organigram Global during the fourth quarter valued at $50,000. Cidel Asset Management Inc. boosted its position in Organigram Global by 112.3% during the second quarter. Cidel Asset Management Inc. now owns 37,103 shares of the company's stock valued at $50,000 after purchasing an additional 19,627 shares during the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new stake in Organigram Global during the second quarter valued at $54,000. Institutional investors and hedge funds own 34.63% of the company's stock.

Organigram Global Company Profile

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.